PROTAGONIST THERAPEUTICS INC (PTGX) Stock Fundamental Analysis
USA - NASDAQ:PTGX - US74366E1029 - Common Stock
78.62 USD
+0.77 (+0.99%)
77.5 USD
-1.12 (-1.42%)
We assign a fundamental rating of 5 out of 10 to PTGX. PTGX was compared to 534 industry peers in the Biotechnology industry. PTGX is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. PTGX does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
PTGX had positive earnings in the past year.
PTGX had a positive operating cash flow in the past year.
In the past 5 years PTGX reported 4 times negative net income.
PTGX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
The Return On Assets of PTGX (7.25%) is better than 92.51% of its industry peers.
PTGX's Return On Equity of 7.79% is amongst the best of the industry. PTGX outperforms 92.70% of its industry peers.
PTGX's Return On Invested Capital of 2.78% is amongst the best of the industry. PTGX outperforms 90.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.25% | ||
| ROE | 7.79% | ||
| ROIC | 2.78% |
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin of PTGX (24.88%) is better than 95.69% of its industry peers.
The Operating Margin of PTGX (11.46%) is better than 92.51% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.46% | ||
| PM (TTM) | 24.88% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PTGX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, PTGX has more shares outstanding
PTGX has more shares outstanding than it did 5 years ago.
PTGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
PTGX has an Altman-Z score of 59.30. This indicates that PTGX is financially healthy and has little risk of bankruptcy at the moment.
PTGX's Altman-Z score of 59.30 is amongst the best of the industry. PTGX outperforms 97.38% of its industry peers.
There is no outstanding debt for PTGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 59.3 |
ROIC/WACC0.32
WACC8.75%
2.3 Liquidity
A Current Ratio of 16.97 indicates that PTGX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 16.97, PTGX belongs to the best of the industry, outperforming 92.70% of the companies in the same industry.
A Quick Ratio of 16.97 indicates that PTGX has no problem at all paying its short term obligations.
PTGX's Quick ratio of 16.97 is amongst the best of the industry. PTGX outperforms 92.70% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 16.97 | ||
| Quick Ratio | 16.97 |
3. Growth
3.1 Past
PTGX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -73.28%.
PTGX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -34.45%.
The Revenue has been growing by 352.10% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-73.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
Revenue 1Y (TTM)-34.45%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%33.09%
3.2 Future
Based on estimates for the next years, PTGX will show a small growth in Earnings Per Share. The EPS will grow by 0.54% on average per year.
Based on estimates for the next years, PTGX will show a small growth in Revenue. The Revenue will grow by 7.60% on average per year.
EPS Next Y-148.36%
EPS Next 2Y-51.05%
EPS Next 3Y-31.32%
EPS Next 5Y0.54%
Revenue Next Year-80.46%
Revenue Next 2Y-31.12%
Revenue Next 3Y-15.85%
Revenue Next 5Y7.6%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 112.31, the valuation of PTGX can be described as expensive.
Based on the Price/Earnings ratio, PTGX is valued cheaper than 90.45% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.11, PTGX is valued quite expensively.
The Forward Price/Earnings Ratio is negative for PTGX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 112.31 | ||
| Fwd PE | N/A |
4.2 Price Multiples
89.51% of the companies in the same industry are more expensive than PTGX, based on the Enterprise Value to EBITDA ratio.
91.57% of the companies in the same industry are more expensive than PTGX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 131.84 | ||
| EV/EBITDA | 152.46 |
4.3 Compensation for Growth
A cheap valuation may be justified as PTGX's earnings are expected to decrease with -31.32% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-51.05%
EPS Next 3Y-31.32%
5. Dividend
5.1 Amount
No dividends for PTGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
78.62
+0.77 (+0.99%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners114.41%
Inst Owner Change-0.94%
Ins Owners1.02%
Ins Owner Change-1.56%
Market Cap4.89B
Revenue(TTM)209.18M
Net Income(TTM)52.04M
Analysts85.26
Price Target78.69 (0.09%)
Short Float %10.44%
Short Ratio5.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)13.09%
Min EPS beat(2)6.78%
Max EPS beat(2)19.4%
EPS beat(4)4
Avg EPS beat(4)135.89%
Min EPS beat(4)6.78%
Max EPS beat(4)504.52%
EPS beat(8)8
Avg EPS beat(8)268.4%
EPS beat(12)10
Avg EPS beat(12)181.29%
EPS beat(16)13
Avg EPS beat(16)138.79%
Revenue beat(2)0
Avg Revenue beat(2)-14.45%
Min Revenue beat(2)-20.11%
Max Revenue beat(2)-8.8%
Revenue beat(4)2
Avg Revenue beat(4)81.15%
Min Revenue beat(4)-20.11%
Max Revenue beat(4)232.24%
Revenue beat(8)4
Avg Revenue beat(8)41.38%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.22%
PT rev (3m)11.32%
EPS NQ rev (1m)-2.69%
EPS NQ rev (3m)-8.83%
EPS NY rev (1m)0.56%
EPS NY rev (3m)-2.47%
Revenue NQ rev (1m)-17.63%
Revenue NQ rev (3m)-52.07%
Revenue NY rev (1m)34.94%
Revenue NY rev (3m)-22.91%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 112.31 | ||
| Fwd PE | N/A | ||
| P/S | 23.38 | ||
| P/FCF | 131.84 | ||
| P/OCF | 123.69 | ||
| P/B | 7.32 | ||
| P/tB | 7.32 | ||
| EV/EBITDA | 152.46 |
EPS(TTM)0.7
EY0.89%
EPS(NY)-1.18
Fwd EYN/A
FCF(TTM)0.6
FCFY0.76%
OCF(TTM)0.64
OCFY0.81%
SpS3.36
BVpS10.74
TBVpS10.74
PEG (NY)N/A
PEG (5Y)N/A
Graham Number13
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.25% | ||
| ROE | 7.79% | ||
| ROCE | 3.51% | ||
| ROIC | 2.78% | ||
| ROICexc | 16.91% | ||
| ROICexgc | 16.91% | ||
| OM | 11.46% | ||
| PM (TTM) | 24.88% | ||
| GM | N/A | ||
| FCFM | 17.74% |
ROA(3y)-12.16%
ROA(5y)-18.6%
ROE(3y)-13.93%
ROE(5y)-21.46%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.29
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 141.54% | ||
| Cap/Sales | 1.17% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 153.85% | ||
| Profit Quality | 71.29% | ||
| Current Ratio | 16.97 | ||
| Quick Ratio | 16.97 | ||
| Altman-Z | 59.3 |
F-Score4
WACC8.75%
ROIC/WACC0.32
Cap/Depr(3y)47.62%
Cap/Depr(5y)67.63%
Cap/Sales(3y)1.45%
Cap/Sales(5y)2%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-73.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-10%
EPS Next Y-148.36%
EPS Next 2Y-51.05%
EPS Next 3Y-31.32%
EPS Next 5Y0.54%
Revenue 1Y (TTM)-34.45%
Revenue growth 3Y151.34%
Revenue growth 5Y352.1%
Sales Q2Q%33.09%
Revenue Next Year-80.46%
Revenue Next 2Y-31.12%
Revenue Next 3Y-15.85%
Revenue Next 5Y7.6%
EBIT growth 1Y-84.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-200.27%
EBIT Next 3Y-30.78%
EBIT Next 5YN/A
FCF growth 1Y131.48%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y133.67%
OCF growth 3YN/A
OCF growth 5YN/A
PROTAGONIST THERAPEUTICS INC / PTGX FAQ
Can you provide the ChartMill fundamental rating for PROTAGONIST THERAPEUTICS INC?
ChartMill assigns a fundamental rating of 5 / 10 to PTGX.
Can you provide the valuation status for PROTAGONIST THERAPEUTICS INC?
ChartMill assigns a valuation rating of 3 / 10 to PROTAGONIST THERAPEUTICS INC (PTGX). This can be considered as Overvalued.
How profitable is PROTAGONIST THERAPEUTICS INC (PTGX) stock?
PROTAGONIST THERAPEUTICS INC (PTGX) has a profitability rating of 4 / 10.
Can you provide the financial health for PTGX stock?
The financial health rating of PROTAGONIST THERAPEUTICS INC (PTGX) is 8 / 10.
Can you provide the expected EPS growth for PTGX stock?
The Earnings per Share (EPS) of PROTAGONIST THERAPEUTICS INC (PTGX) is expected to decline by -148.36% in the next year.